• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Eisai cuts to hit U.S. workforce

Eisai cuts to hit U.S. workforce

March 9, 2011
CenterWatch Staff

More details are being released about Japanese drugmaker Eisai’s previously announced five years of job cuts totaling 900 positions. Eisai intends to slice 20% of its work force, or 600 jobs, in the U.S., by April 1.

The cuts are more immediate than Eisai hinted at when announcing its five-year plan. Citing the loss of patent protection on its lead drug, the Alzheimer's treatment Aricept, the company predicted flat sales over the next several years. To handle that lack of growth, Eisai said it would pare back its payroll by 900 positions by 2015. Cuts would be spread over Japanese, U.S. and European operations, it said.

The U.S. cuts are part of the 900-person cutback, a spokeswoman told Bloomberg. Two hundred European positions will go, as will 100 sales jobs in Japan.

"This restructuring is essential to our remaining competitive in this rapidly changing environment," Lonnel Coats, president and CEO of Eisai's U.S. unit, said in a statement. "It will enable us to continually make the necessary investments in our science, our people and ultimately our human health care mission."

One bit of good news for the U.S. is that no primary offices or facilities will be closed, the company said. Eisai's U.S. operations include R&D, manufacturing, sales and marketing and administrative functions, according to a company statement.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing